Syndax Pharmaceuticals, Inc. insider trading

Bought

—

Sold

$2.1M

3 of 5 on a 10b5-1 plan

Net

−$2.1M

Insiders

3

• Metzger Michael A10b5-1

  Chief Executive Officer · Director

  −$784.8K

  Jul 08, 2026

  32,375 sh · $24.24

• Botwood Nicholas A.J.10b5-1

  Head of R&D, CMO

  −$566.6K

  Jun 12, 2026

  31,235 sh · $18.14

• Botwood Nicholas A.J.10b5-1

  Head of R&D, CMO

  −$617K

  Jun 11, 2026

  34,280 sh · $18.00

• Goldan Keith A.

  Chief Financial Officer

  −$22.4K

  Jun 01, 2026

  1,177 sh · $18.99

• Metzger Michael A

  Chief Executive Officer · Director

  −$130K

  Jun 01, 2026

  6,847 sh · $18.99

Largest purchase

+$105.9K of SNDX by Botwood Nicholas A.J. (Head of R&D, CMO) on May 16, 2025.

Largest sale

−$2.6M of SNDX by Metzger Michael A (Chief Executive Officer · Director) on Sep 08, 2025, under a 10b5-1 plan.

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

SEC industry classification

Pharmaceutical Preparations

Headquarters

New York, NY

Incorporated in

DE

Listed on

Nasdaq

SEC Central Index Key

0001395937

Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.

The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.

Open-market purchase (code P)

An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.

Grants and option exercises (codes A, M)

Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.

Cluster buy

Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.

Are SNDX insiders buying or selling?

Between Jun 01, 2026 and Jul 08, 2026, 3 Syndax Pharmaceuticals, Inc. insiders made no open-market purchases and 5 sales worth $2.1M, a net sale of $2.1M. 3 of the sales were pre-scheduled under a Rule 10b5-1 plan.

How much SNDX stock have insiders bought and sold in the last two years?

Between Jul 01, 2024 and Jun 30, 2026, 7 Syndax Pharmaceuticals, Inc. insiders made 3 open-market purchases worth $241.9K and 18 sales worth $6M. 7 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: no purchases and 14 sales ($5.5M). The largest purchase was Botwood Nicholas A.J. buying $105.9K on May 16, 2025. The largest sale was Metzger Michael A selling $2.6M on Sep 08, 2025.

What was the largest recent SNDX insider trade?

Metzger Michael A (Chief Executive Officer · Director) sold $784.8K of SNDX stock on Jul 08, 2026 at about $24.24 a share, under a pre-scheduled 10b5-1 plan.

When did an insider last buy SNDX shares?

No open-market purchase by a Syndax Pharmaceuticals, Inc. insider appears in the filings from Jun 01, 2026 to Jul 08, 2026 — every recorded open-market transaction in that period was a sale. Before that, the most recent purchase in SEC's data was Katkin Keith buying $91.1K on May 19, 2025.

Where does SNDX insider trading data come from?

From the Form 4 filings Syndax Pharmaceuticals, Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.